Althexis secures €400,000 investment to accelerate the market penetration of Skincare Suite
Athens, Greece – February 11, 2025 — Digital Health company Althexis has secured a €400,000 funding round led by Corallia Ventures TT with participation from angel investors. The investment will accelerate the commercial rollout of its proprietary Skincare Suite Platform, a data-driven sales optimization solution designed to help physical pharmacies compete with e-commerce, by significantly enhancing personalized sales and boosting high-margin skincare revenues by 25% in pilot deployments.
Revenue Uplift and In-Store Experience
Althexis addresses the critical challenge physical pharmacies face today in differentiating from competition while driving high-margin and recurrent sales. The Skincare Suite Platform uses proprietary multispectral imaging technology and generative AI to precisely analyze multiple critical skin parameters like oiliness, hydration, texture, discoloration, sebum levels and sub-surface characteristics, combined with customer profiles and pharmacy’s product inventory and instantly generates highly personalized, scientifically grounded skin care routines based on each pharmacy’s inventory enhancing in-store experience, trust, and conversion rates.
Dual Value Streams: Retail and Business Intelligence
In a seamless 3-minute in-store session, Althexis transforms the pharmacy staff into trusted, data-driven skincare experts, integrating objective skin diagnostics into the sales workflow. The solution creates value for two core stakeholders: Pharmacies benefit from a scalable solution that drives sales, improves customer retention through personalized post-visit follow-ups, and strengthens long-term customer loyalty. Skincare Manufacturers access an anonymized business intelligence platform providing detailed market insights, customer demographic data and targeted opportunities for sponsored product placement slots at the point of care.
“This investment validates the critical transformation happening in retail pharmacy.” said Dr. Antonis Nikitakis, Co-founder and CEO of Althexis. “Over the last years, pharmacies have beautifully evolved: moving from sterile dispensaries into inviting, experience-focused retail destinations that emphasize customer exploration and comfort. However, this transformation has been largely aesthetic. The core challenge remains: most in-store skincare recommendations still rely on guesswork or require costly, specialized personnel, creating a significant gap in customer trust and sales consistency.”.
Thanasis Papathanasiou, Co-founder & CTO added: ‘‘We are now entering the essential second phase: bringing science directly to the sales floor. Althexis’s Skincare Suite uses advanced dermoscopy and AI to eliminate the guesswork. We empower every pharmacy staff member to offer highly personalized, scientific recommendations in minutes. This approach is proven to build long-term loyalty, drive customer confidence, and most critically, deliver a significant revenue uplift that keeps physical pharmacies competitive against e-commerce.”
Backed by leading investors
Dr. Jorge-A. Sanchez-P., Partner at Corallia Ventures TT, stated: ”Althexis is a compelling example of how deep scientific expertise can be translated into a scalable, commercially robust digital health product. What impressed us is not only the strength of the underlying multispectral and AI technology, but the team’s clear understanding of the unmet need for science-driven personalization in the pharmacy channel. At Corallia Ventures, we invest in companies that can build global relevance from Greece. Althexis has all the key ingredients: defensible technology, a strong founding team, and a business model that aligns incentives across pharmacies and skincare brands. We are excited to support the company as it validates the model in Greece and scales globally.”
Pablo Pinedo David, Angel Investor added: “What convinced me to invest in Althexis is its strategic position within the value chain. The company transforms a traditionally under-optimized environment into a data-driven growth engine, while preserving the human trust that makes pharmacies truly stand out.”
Dimitris Tsingos, Co-Founder of HeBAN – Hellenic Business Angels Network, commented:
“At the Hellenic Business Angels Network, we are delighted to participate in Althexis’ funding round. We believe the company has outstanding growth prospects and that the meaningful and productive application of Artificial Intelligence in the healthcare sector creates significant opportunities for rapid international expansion. HeBAN, which now brings together more than 100 angel investors, is committed to prioritizing investment schemes emerging from the Greek research and innovation ecosystem, making our enthusiasm for this particular investment even greater.”
Next steps and expansion strategy
The funding will accelerate market penetration in Greece, serving as a market validation phase to further expand globally. Althexis is already establishing partnerships with leading pharmacy chains and skincare manufacturers in preparation for European expansion. The company plans to enter key markets, including Italy and Spain from 2026, with the goal of becoming the leading global provider of science-driven sales technology for physical skincare retail.
About Althexis
Althexis P.C. is a Greek digital health startup bridging advanced dermoscopy with AI-powered sales optimization for the skincare retail sector. By synthesizing multispectral imaging with predictive analytics, Althexis transforms clinical-grade skin analysis into high-conversion, personalized product recommendations, effectively closing the gap between dermatological science and commercial performance.
For more info visit: https://althexis.com/